Financial giants have made a conspicuous bearish move on ResMed. Our analysis of options history for ResMed (NYSE:RMD) revealed 10 unusual trades.
Delving into the details, we found 20% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $110,805, and 8 were calls, valued at $345,662.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $170.0 to $230.0 for ResMed over the last 3 months.
Insights into Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for ResMed's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across ResMed's significant trades, within a strike price range of $170.0 to $230.0, over the past month.
ResMed 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
About ResMed
In light of the recent options history for ResMed, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of ResMed
- Trading volume stands at 392,372, with RMD's price down by -0.22%, positioned at $208.09.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 2 days.
Professional Analyst Ratings for ResMed
1 market experts have recently issued ratings for this stock, with a consensus target price of $204.0.
- An analyst from RBC Capital has decided to maintain their Sector Perform rating on ResMed, which currently sits at a price target of $204.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ResMed with Benzinga Pro for real-time alerts.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
